1. Home
  2. ASA vs ANAB Comparison

ASA vs ANAB Comparison

Compare ASA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASA
  • ANAB
  • Stock Information
  • Founded
  • ASA 1958
  • ANAB 2005
  • Country
  • ASA United States
  • ANAB United States
  • Employees
  • ASA N/A
  • ANAB N/A
  • Industry
  • ASA Precious Metals
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASA Industrials
  • ANAB Health Care
  • Exchange
  • ASA Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • ASA 622.9M
  • ANAB 621.1M
  • IPO Year
  • ASA N/A
  • ANAB 2017
  • Fundamental
  • Price
  • ASA $32.46
  • ANAB $22.50
  • Analyst Decision
  • ASA
  • ANAB Buy
  • Analyst Count
  • ASA 0
  • ANAB 10
  • Target Price
  • ASA N/A
  • ANAB $44.25
  • AVG Volume (30 Days)
  • ASA 54.0K
  • ANAB 659.2K
  • Earning Date
  • ASA 07-15-2025
  • ANAB 08-04-2025
  • Dividend Yield
  • ASA 0.12%
  • ANAB N/A
  • EPS Growth
  • ASA N/A
  • ANAB N/A
  • EPS
  • ASA 11.67
  • ANAB N/A
  • Revenue
  • ASA $3,557,386.00
  • ANAB $111,872,000.00
  • Revenue This Year
  • ASA N/A
  • ANAB N/A
  • Revenue Next Year
  • ASA N/A
  • ANAB $24.39
  • P/E Ratio
  • ASA $2.70
  • ANAB N/A
  • Revenue Growth
  • ASA 45.39
  • ANAB 387.20
  • 52 Week Low
  • ASA $17.42
  • ANAB $12.21
  • 52 Week High
  • ASA $35.00
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • ASA 52.55
  • ANAB 45.71
  • Support Level
  • ASA $30.35
  • ANAB $22.49
  • Resistance Level
  • ASA $32.21
  • ANAB $24.86
  • Average True Range (ATR)
  • ASA 0.95
  • ANAB 1.15
  • MACD
  • ASA -0.30
  • ANAB -0.27
  • Stochastic Oscillator
  • ASA 49.53
  • ANAB 0.00

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: